Stem cell and exosome therapy for COPD in Istanbul, Turkey
Individualized intravenous Wharton's jelly MSC and exosome protocols designed to modulate chronic pulmonary inflammation and support alveolar microvascular balance alongside your regular respiratory care.
Understanding COPD and how pulmonary regenerative biologics support lung tissue
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition driven by a self-perpetuating cycle of small-airway inflammation, protease-antiprotease imbalance, oxidative injury, and microvascular stress across the alveolar-capillary membrane. Even when external irritants are eliminated, overactive alveolar macrophages, neutrophils, and cytotoxic T cells continue releasing tissue-degrading enzymes and inflammatory cytokines that thicken bronchial walls, trap mucus, and weaken gas-exchange surfaces. In daily life, this ongoing pulmonary inflammation manifests as breathlessness on exertion, chronic cough, frequent respiratory flare-ups, and exhausting physical fatigue.
Intravenous Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are uniquely positioned to target the lungs through a natural physiological mechanism known as the **pulmonary first-pass effect**. Following intravenous infusion, WJ-MSCs travel directly through the right side of the heart into the dense capillary network of the lungs, where they temporarily reside and respond directly to local inflammatory signals. Within this pulmonary microenvironment, WJ-MSCs and their nanoscale exosomes release anti-inflammatory cytokines (such as IL-10 and TSG-6), growth factors (HGF, VEGF, KGF), and regulatory microRNAs that shift destructive M1 alveolar macrophages toward reparative M2 phenotypes, calm neutrophil-driven protease damage, reduce oxidative stress, and support the delicate endothelial cells lining the alveolar capillaries.
At our Istanbul clinic led by Uzm. Dr. Cihan Bolat, you begin by submitting your spirometry results, chest CT reports, resting oxygen saturation, and medical history. Our medical team evaluates your respiratory stability to design a personalized intravenous WJ-MSC and exosome protocol—working alongside your prescribed inhalers to help calm airway inflammation, support microvascular gas-exchange efficiency, and improve your daily breathing comfort and stamina.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the lungs in COPD—and how WJ-MSCs and exosomes help repair it
Four interconnected biological processes drive chronic airflow limitation and gas-exchange stress in COPD—each providing a direct target for intravenous cellular and exosome signaling.
Therapeutic objectives of our COPD protocol
Our intravenous WJ-MSC and exosome protocols in Istanbul focus on supporting and repairing the pulmonary biological environment while you continue your prescribed bronchodilators and respiratory regimen at home.
In COPD, alveolar macrophages become locked in a pro-inflammatory M1 state, recruiting waves of neutrophils and CD8+ T cells that flood the bronchioles and alveoli with TNF-alpha, IL-1beta, IL-6, and IL-8.
Arriving in the lung microvasculature via the pulmonary first-pass effect, WJ-MSCs and exosomes release immunomodulatory factors (IL-10, PGE2, TSG-6) that reprogram alveolar macrophages from destructive M1 phenotypes toward reparative, tissue-protective M2 states, quieting chronic bronchial inflammation.
Excessive release of neutrophil elastase and matrix metalloproteinases (MMP-9, MMP-12) overwhelms the lung's natural antiprotease shield, degrading elastic fibers in the alveolar walls and impairing elastic recoil during exhalation.
By calming neutrophil recruitment and transferring regulatory exosomal microRNAs, WJ-MSC and exosome therapy helps restore protease-antiprotease balance and secrete tissue inhibitors of metalloproteinases (TIMPs) that protect the remaining extracellular elastin and collagen scaffold.
High levels of reactive oxygen species (ROS) injure ciliated bronchial epithelial cells, stimulate goblet-cell mucus hypersecretion, and trigger peribronchiolar fibrosis that narrows the small airways.
Wharton's jelly MSCs and exosomes deliver antioxidant enzymes (such as superoxide dismutase and catalase) alongside epithelial trophic factors like KGF and HGF, supporting the repair of stressed airway epithelium, moderating fibrotic wall thickening, and improving mucociliary clearance.
04
Alveolar-capillary microvascular stress & hypoxia
Chronic inflammation and elevated pulmonary vascular resistance damage the delicate capillary endothelial cells surrounding the alveoli, impairing oxygen diffusion into the bloodstream and straining cardiopulmonary stamina.
Through paracrine secretion of VEGF and angiopoietin-1, WJ-MSCs and their exosomes nourish pulmonary capillary endothelial cells, reduce microvascular permeability, and support healthier perfusion across remaining gas-exchange surfaces.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological repair rationale
Quieting the chronic inflammatory engine in the lungs
In COPD, persistent activation of innate and adaptive immune cells inside the small airways and alveoli creates a hostile microenvironment where proteolytic enzymes (such as neutrophil elastase and matrix metalloproteinases) outpace natural tissue defenses. This chronic inflammation damages capillary endothelial cells and impairs the local progenitor cells responsible for maintaining bronchial and alveolar epithelium.
Targeting this inflammatory and oxidative cascade with biological immunomodulators aims to restore tissue equilibrium and protect remaining functional lung parenchyma from ongoing inflammatory wear.
Synergistic cellular & vesicular action
Leveraging the pulmonary first-pass effect with WJ-MSCs and exosomes
Unlike oral or systemic drugs that dilute across the entire body before reaching the lungs, intravenously infused Wharton's jelly MSCs encounter the pulmonary capillary bed as their very first microvascular filter. Here, live WJ-MSCs interact directly with pulmonary endothelial cells and resident immune populations, secreting keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF).
Simultaneously, co-administered WJ-MSC exosomes penetrate deep into bronchial and alveolar tissues to transfer anti-inflammatory microRNAs and mitochondrial-protective proteins that help repair stressed respiratory epithelial cells and calm mucosal hyperreactivity.
Individualized clinical planning
Protocols tailored to your respiratory profile and flight stability
Because COPD encompasses a wide spectrum—from chronic bronchitis-predominant airway inflammation to emphysematous alveolar stress—our medical team evaluates your spirometry (FEV1/FVC), chest CT findings, oxygen saturation, and cardiac status before recommending a protocol.
Uzm. Dr. Cihan Bolat's team structures your staged intravenous infusions in Istanbul with careful pulse oximetry and clinical monitoring, ensuring that regenerative support integrates safely with the maintenance bronchodilators and respiratory care managed by your home pulmonologist.
Our treatment approach & administration routes
Our COPD biologics and administration routes
Every COPD protocol is built around intravenous Wharton's jelly biologics that leverage natural pulmonary circulation dynamics to reach the lung microvasculature directly.
01
Intravenous Wharton's Jelly MSC Infusion
Administered via peripheral intravenous infusion, GMP-cultivated Wharton's jelly MSCs travel immediately to the pulmonary capillary bed through the physiological pulmonary first-pass effect. As they interact with the lung microvasculature, these metabolically active cells sense local inflammatory cytokines and release a sustained stream of immunomodulatory and trophic factors (HGF, VEGF, KGF, IL-10) right where airway and alveolar inflammation is concentrated.
Role in your protocolCell dosage, infusion volume, and delivery rate are individually calibrated to your cardiopulmonary baseline and resting oxygen saturation.
02
Intravenous WJ-MSC Exosome Administration
Purified Wharton's jelly MSC-derived exosomes circulate seamlessly through the bronchial and alveolar microvasculature, crossing endothelial barriers to enter stressed respiratory epithelial cells and resident macrophages. Their nanoscale cargo of anti-inflammatory microRNAs and signaling proteins works to downregulate NF-kappaB inflammatory signaling, reduce oxidative stress, and support cellular energy repair.
Role in your protocolProvides high-concentration acellular paracrine signaling without adding cellular volume to the pulmonary capillary bed.
03
M1-to-M2 Macrophage & Cytokine Modulation
By pairing live WJ-MSCs with concentrated WJ-MSC exosomes, our protocol targets the core immune dysregulation of COPD: shifting pulmonary macrophages from tissue-degrading M1 states into reparative M2 states, expanding regulatory T cells (Tregs), and lowering systemic and pulmonary levels of TNF-alpha, IL-1beta, IL-6, and C-reactive protein (CRP).
Role in your protocolAims to quiet both local small-airway irritation and the systemic inflammatory spillover that causes muscle fatigue and low stamina in COPD.
04
Staged Istanbul Infusion & Monitoring Schedule
Rather than delivering all biologics in a single bolus, our medical team structures your protocol across staged outpatient sessions over several days in Istanbul. Each session includes pre- and post-infusion pulse oximetry, blood-pressure and heart-rate monitoring, and laboratory checks of systemic inflammatory markers.
Role in your protocolYou continue your regular maintenance inhalers throughout your stay and receive a complete medical report to share with your home pulmonologist.
What we aim to achieve
How we track respiratory and systemic progress
We establish baseline clinical and laboratory benchmarks in Istanbul and connect the biological mechanisms of pulmonary repair to practical functional outcomes over three, six, and twelve months.
01
Systemic & pulmonary inflammatory biomarkers
Elevated C-reactive protein (CRP) and inflammatory white-blood-cell ratios reflect active inflammatory spillover from the lungs into the systemic circulation. By calming alveolar macrophage and neutrophil activation, we track reductions in CRP and inflammatory markers before and after your protocol.
02
Exertional stamina, walking distance & saturation
When small-airway mucosal swelling subsides and pulmonary capillary perfusion is supported, patients often evaluate progress through everyday physical endurance—such as walking farther with less breathlessness, climbing stairs more comfortably, and maintaining steadier pulse oximetry saturation during routine exertion.
03
Airway comfort, mucus burden & flare intervals
Acute COPD exacerbations are frequently triggered by smoldering bronchial inflammation and impaired mucociliary clearance. Supporting epithelial repair and M2 macrophage balance aims to reduce daily coughing and phlegm tenacity while lengthening the stable intervals between respiratory flare-ups.
04
Longitudinal spirometry & pulmonology follow-up
We provide a detailed medical summary of your administered WJ-MSC and exosome doses and baseline Istanbul labs so your home pulmonologist can compare serial spirometry (FEV1, FVC) and diffusion capacity alongside your ongoing inhaler regimen.
How treatment is personalized
How our 6-step pulmonary evaluation works
You begin by sharing your spirometry results, chest imaging, and medication list. Our medical team under Uzm. Dr. Cihan Bolat evaluates your respiratory stability and flight fitness, develops an individualized IV WJ-MSC and exosome protocol where appropriate, and explains all treatment details and costs before you plan your trip to Istanbul.
Medical history & reports we request
Recent spirometry (FEV1, FVC) and pulmonary function test reports
Chest CT scan or chest X-ray reports and resting oxygen saturation levels
History of recent exacerbations, steroid or antibiotic courses, and any oxygen use
Complete list of current maintenance inhalers and systemic medications
Cardiovascular history, echocardiogram reports if available, and recent blood work
Clinical suitability & timing checks
Active acute COPD exacerbation, fever, or untreated respiratory tract infection
Unstable hypoxemia or decompensated heart failure that makes commercial air travel unsafe
Severe uncontrolled pulmonary hypertension or acute thromboembolic disease
Any acute medical condition requiring immediate inpatient hospital stabilization
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
COPD stem cell and exosome therapy cost in Istanbul
Once our medical team evaluates your pulmonary records and imaging, you receive an itemized written treatment plan outlining the recommended intravenous WJ-MSC count, WJ-MSC exosome dosage, number of sessions, clinical monitoring, and total cost.
For context, our 2026 systemic Wharton's jelly MSC and exosome programs generally range from $7,000 to $18,000 depending on biologic dosage and the number of staged infusions.
Total intravenous Wharton's jelly MSC dose and WJ-MSC exosome concentration
Number of staged IV infusion sessions scheduled during your stay in Istanbul
Pre- and post-treatment laboratory panels and clinical oximetry monitoring
Physician consultations and coordinated VIP airport, hotel, and clinic transfers
How does the pulmonary first-pass effect work when WJ-MSCs and exosomes are given intravenously?
02
Am I stable enough to fly to Istanbul based on my current spirometry and oxygen saturation?
03
How many days should I plan to stay in Istanbul for my COPD infusion protocol?
04
How does this protocol fit alongside the inhalers prescribed by my pulmonologist?
Evidence & important considerations
Published clinical evidence in COPD cell research
Controlled clinical trials and systematic reviews evaluate the safety, systemic inflammatory biomarkers, and functional endpoints of intravenous mesenchymal stromal cells in COPD.
Confirmed strong procedural safety and tolerability while documenting reductions in systemic C-reactive protein (CRP) in patients with elevated baseline inflammation.
Limitation
Did not demonstrate a statistically significant change in spirometric FEV1 over the study window, indicating that biological modulation does not equate to structural alveolar regrowth.
We administer GMP-prepared Wharton's jelly MSCs and WJ-MSC-derived exosomes intravenously. Because venous blood flows directly to the lungs first (the pulmonary first-pass effect), infused cells and vesicles interact directly with the pulmonary microvasculature to release anti-inflammatory and trophic signals.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
